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Conclusions: An IL-20 ELISA has been developed and further samples 
are being collected for analysis. Based on these ﬁndings that IL-20 is 
up-regulated by TSA and under epigenetic control, targeting this cy-
tokine may be used as a potential anti-angiogenic approach in making 
lung cancer history.
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A number of growth-factor-receptor-targeted agents have been tried 
with encouraging results in patients with advanced NSCLC (Noble et 
al 2006). Women, non-smokers, adenocarcinoma and Asians respond 
better. This communication is our further experience of our earlier 
presentation. 
Histologically proven advanced (stage IIIB or IV) non-small cell lung 
cancer patients earler treated with chemotherapy received geﬁtinib 
(Geﬁtinat) 250mg daily orally. There were 28 females (38-57 yrs) and 
67 males (44-67 yrs). Fifty four were non-smokers and the remaining 
were smokers. Sixty two had adenocarcinoma and 33 had squamous 
cell carcinoma. The disease was of stage IIIB (n=58) and stage IV 
(n=37). The duration of geﬁtinib therapy varied from 20 weeks to 58 
weeks with median of 29.5 weeks. The disease remained static in 66 
(69%) with stabilization or improvement in the Kornofsky performance 
scales in 73. The mean performance status improved from 70 to 90 
in 34 cases, deteriorated in 13 and in the remaining remained static at 
90. There was no radiological progression in 43 cases, while 28 cases 
showed radiological progression. The median survival (calculated after 
completion of chemotherapy and start of geﬁtinib) was 33 weeks with 
22 patients surviving beyond 1 year. The drug was well tolerated by 
all. Thirty three patients complained of mild skin rash (three ﬁxed drug 
eruption). 29 patients had grade 1-2 diarrhoea. 
We found geﬁtinib as beneﬁcial The drug is well tolerated by Indian 
patients.This may be due to a different pharmacogenomic property of 
geﬁtinib in this population. 
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Background: VEGF expression has been correlated with increased 
tumor angiogenesis and shortened survival in NSCLC, and inhibition 
of the VEGF and also the EGF signaling pathways has a demonstrated 
treatment beneﬁt in this malignancy. Therefore, a treatment strategy 
combining agents that speciﬁcally inhibit both signaling pathways may 
further improve patient outcome. Sunitinib malate is an oral, multitar-
geted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, RET and 
FLT3, approved multinationally for the treatment of advanced renal cell 
carcinoma and imatinib-resistant or -intolerant gastrointestinal stromal 
tumor. A multicenter phase II trial of sunitinib administered on a 4/2 
schedule (4 weeks on treatment followed by 2 weeks off) in recurrent 
advanced NSCLC demonstrated an 11% objective response rate among 
patients treated second- or third-line (Socinski, ESMO 2006). Here 
we report the results of a lead-in safety study assessing the safety and 
tolerability of sunitinib combined with erlotinib in locally advanced or 
metastatic NSCLC after failure of chemotherapy. If the safety proﬁle 
of the combination is favorable, 126 patients will be randomized to 
sunitinib plus erlotinib or to placebo plus erlotinib in a phase II portion 
of the study.
Methods: The lead-in safety cohort was planned to include 10 patients 
evaluable for the safety and tolerability of sunitinib combined with 
erlotinib, with additional patients enrolled if needed to obtain adequate 
pharmacokinetic data. Patients were eligible if they had histologically 
proven, stage IIIB or IV NSCLC; had received 1 or 2 prior chemothera-
py regimens, including a platinum-based regimen; measurable disease; 
ECOG PS 0 or 1, and adequate organ function. Treatment comprised 
sunitinib 37.5 mg/day continuously plus erlotinib 150 mg/day, given 
orally, in repeated 4-week cycles. Patients were observed for dose-lim-
iting toxicities (DLTs) during the ﬁrst 28 days of treatment.
Results: Twelve patients were treated in the lead-in cohort, with the 
following baseline characteristics: median age 62 years (range 47-75); 
6 male; histology 9 adenocarcinoma, 1 squamous cell carcinoma, 2 
other; history of smoking in 8 patients. The patients started a median of 
2 cycles (range 1-5), with dose reductions in 5 patients (erlotinib, n=2; 
sunitinib, n=1; both, n=2). Two patients developed a DLT (both grade 3 
fatigue lasting at least 7 days). Adverse events were generally mild-to-
moderate in severity (grade 1/2). Seven patients experienced grade 3 
adverse events that included diarrhea (n=3), fatigue (n=2), acne (n=1), 
anemia (n=1), dehydration (n=1), diffuse skin rash (n=1), pruritus 
(n=1) and paronychial inﬂammation (n=1); no grade 4/5 events were 
reported. Pharmacokinetic analyses are ongoing.
Conclusions: Sunitinib 37.5 mg/day given continuously with erlo-
tinib 150 mg/day was safe and tolerable in this cohort of patients with 
advanced NSCLC. The efﬁcacy and safety of sunitinib combined with 
erlotinib will be investigated further in the randomized phase II portion 
of this study. 
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Background: In non-small cell lung cancer (NSCLC) preclinical 
models, celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, potentiates 
the apoptotic and growth inhibitory effects of erlotinib, an epidermal 
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). We 
designed a phase II trial to evaluate the clinical efﬁcacy and safety of 
erlotinib plus celecoxib in advanced NSCLC. 
